MEK inhibitors were reported to increase susceptibility of melanoma cells to CTL lysis partly due to increased expression of melanosomal antigens such as MART-1/melan-A and gp100 (Kono et al., 2006; Boni et al., 2010). This evidence concerns the gene PMEL and melanoma.